Reid-Rowell's Rowasa (mesalamine) suppository
Executive Summary
New dosage form is now being promoted by sales reps and advertised in gastroenterology journals. Shipments to wholesalers of the 500 mg suppository product began on Jan. 7. The suppository was approved Dec. 18 for treatment of active ulcerative proctitis. The Rowasa suspension enema, approved in December 1987 for treatment of active mild-to-moderate distal ulcerative colitis, proctosigmoiditis or proctitis, was the first 5-ASA product to enter the market.
|
New dosage form is now being promoted by sales reps and advertised
in gastroenterology journals. Shipments to wholesalers of the 500
mg suppository product began on Jan. 7. The suppository was
approved Dec. 18 for treatment of active ulcerative proctitis. The
Rowasa suspension enema, approved in December 1987 for treatment of
active mild-to-moderate distal ulcerative colitis,
proctosigmoiditis or proctitis, was the first 5-ASA product to
enter the market. |